Adimmune Corporation (TWSE: 4142) today announced that both Adimmune and its subsidiary, Enimmune Corp. (TWSE: 6564), have been honored with the Gold Award for Corporate Epidemic Prevention, and recognized among the Top 10 Vaccine News of 2025.   

The awards were organized by the Taiwan Immunization Vision and Strategy (TIVS), under its Corporate Epidemic Prevention Alliance program. A total of 41 companies received Gold, Silver, or Bronze awards this year. Adimmune and Enimmune were both granted the Gold awards, with the honor presented by Mr. Lin Ming-Cheng, Deputy Director-General of the Taiwan Centers for Disease Control.   

TIVS noted that award-winning companies share three key characteristics: proactively planning vaccination education and health promotion initiatives; establishing vaccination areas or arranging medical professionals to administer vaccines; and implementing incentive programs covering employees and, in some cases, their family members. These efforts demonstrate a comprehensive health protection framework that extends “from the workplace to the family,” reflecting a shift in corporate mindset—vaccination is no longer viewed merely as an employee benefit, but as a critical component of organizational resilience, operational risk management, and sustainable governance.   

Adimmune Group has long provided free influenza vaccinations to employees and their family members, achieving a vaccination coverage rate exceeding 70%. In recent years, the Group has further expanded its preventive measures by offering free tetanus vaccinations to employees in high-risk roles and free enterovirus vaccinations for employees’ young children, establishing a more comprehensive epidemic prevention network for employees and their families across all age groups.   

In addition, developments involving Adimmune and Enimmune were also selected for inclusion in the Top 10 Vaccine News of 2025, announced on the same day. Highlights included progress in Adimmune’s regulatory approval for influenza vaccines in the Southern Hemisphere as well as Enimmune’s regulatory application in Vietnam. TIVS cited industry momentum as a major theme this year, noting milestones such as Adimmune’s renewed GMP certification in Brazil, with a target to obtain regulatory approval for Southern Hemisphere influenza vaccines by the end of 2026, and Enimmune’s Enterovirus 71 vaccine advancing into the Vietnamese market—both underscoring the growing international competitiveness of Taiwan’s vaccine industry.   

Prof. Huang Yhu-Chering, Executive Director of TIVS, emphasized that the vaccine industry is highly strategic and technologically intensive. He noted that by continuing to strengthen capabilities in manufacturing processes, biologics quality, and supply chain management, Taiwan has the potential to further enhance its strategic position in the Asia-Pacific vaccine market. He also expressed his expectation that Adimmune will continue to advance its influenza vaccine development, including formulations tailored for the elderly population, to further contribute to public health in Taiwan.